Prelude Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Prelude Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.22M	Buy	+56,673	New	+$799K	0.09%	257
2025 Q4	–	Sell	-10,641	Closed	-$75K	–	1351
2025 Q3	$75K	Sell	10,641 -8,898	-46%	-$61.2K	0.01%	1079
2025 Q2	$127K	Buy	+19,539	New	+$134K	0.01%	876
2024 Q1	–	Sell	-42,500	Closed	-$621K	–	1358
2023 Q4	$621K	Buy	42,500 +20,600	+94%	+$250K	0.04%	426
2023 Q3	$269K	Buy	21,900 +10,000	+84%	+$130K	0.02%	735
2023 Q2	$142K	Buy	+11,900	New	+$155K	0.01%	891

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Prelude Capital Management's DAWN Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Day One Biopharmaceuticals (DAWN) in Q1 2026: 56,673 shares worth $1.22M. The stake represents 0.09% of the portfolio and ranks #257 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in DAWN as recently as Q3 2025.

Prelude Capital Management first reported a position in DAWN in Q2 2023 and has held it in 6 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Prelude Capital Management held 56,673 shares of Day One Biopharmaceuticals worth $1.22M as of Q1 2026.
Day One Biopharmaceuticals was a new Prelude Capital Management position in Q1 2026.
Day One Biopharmaceuticals made up 0.09% of Prelude Capital Management's portfolio in Q1 2026, its #257 holding.
Prelude Capital Management first reported a position in Day One Biopharmaceuticals in Q2 2023 and has held it in 6 quarters since.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.